ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced major advancements in the process of bringing its Retinal Pigment Epithelial (RPE) program into the clinic to treat various retinal degenerative diseases, including Age-Related Macular Degeneration (AMD). After preliminary discussions earlier this year with staff from the Office of Cellular, Tissue, and Gene Therapies within the Center for Biologics Evaluation and Research at the Food and Drug Administration (FDA), the company has contracted with a leading contract research organization in order to commence work on an extensive preclinical program. Earlier this month, MPI Research, located in Mattawan, Michigan, initiated pilot studies under Good Laboratory Practices (GLP) for Advanced Cell Technology’s (ACT) ongoing RPE program.
